How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/haemophilus-influenzae-chronic-bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Haemophilus Influenzae Chronic Bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Haemophilus Influenzae Chronic Bronchitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Haemophilus Influenzae Chronic Bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	Cephalosporin Antibacterial		2001-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Cedax	ceftibuten	Burke Therap	Cephalosporin Antibacterial		1995-01-01
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Azo Gantanol	SULFAMETHOXAZOLE	Pfizer	Sulfonamide Antimicrobial [EPC]		1973-01-01
Trimethoprim	TRIMETHOPRIM	Dr Reddys Labs Sa	Sulfonamide Antimicrobial [EPC]	Dihydrofolate reductase	1973-01-01
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 7 drugs in Haemophilus Influenzae Chronic Bronchitis
GSK · 2 drugs in Haemophilus Influenzae Chronic Bronchitis
Assistance Publique - Hôpitaux de Paris · 1 drug in Haemophilus Influenzae Chronic Bronchitis
Bayer AG · 1 drug in Haemophilus Influenzae Chronic Bronchitis
Bristol-Myers Squibb · 1 drug in Haemophilus Influenzae Chronic Bronchitis
Burke Therap · 1 drug in Haemophilus Influenzae Chronic Bronchitis
Dr Reddys Labs Sa · 1 drug in Haemophilus Influenzae Chronic Bronchitis
Allergan · 1 drug in Haemophilus Influenzae Chronic Bronchitis
Generic (originally Beecham/GSK) · 1 drug in Haemophilus Influenzae Chronic Bronchitis
King George's Medical University · 1 drug in Haemophilus Influenzae Chronic Bronchitis
Novartis Pharmaceuticals · 1 drug in Haemophilus Influenzae Chronic Bronchitis
Pfizer · 1 drug in Haemophilus Influenzae Chronic Bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Haemophilus Influenzae Chronic Bronchitis:

Cite this brief

Drug Landscape (2026). Haemophilus Influenzae Chronic Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/haemophilus-influenzae-chronic-bronchitis. Accessed 2026-06-10.

Haemophilus Influenzae Chronic Bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing